Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
NCT04559815 (Canada), NCT04537637 (Denmark), NCT05230615 (Italy), NCT04601740 (the Netherlands), NCT04601753 (Sweden), NCT04537624 (Switzerland), NCT04862923 (UK).
Authors
- William van Houtum
- Uffe Christian Braae (ORCID: https://orcid.org/0000-0002-2743-4584)
- Anastas Kick (ORCID: https://orcid.org/0009-0001-8132-8299)
- Hanan Amadid (ORCID: https://orcid.org/0000-0001-5759-4960)
- Klaus Roslind (ORCID: https://orcid.org/0000-0002-9612-5291)
- Gottfried Rudofsky (ORCID: https://orcid.org/0000-0002-2576-7190)
- Sergiu‐Bogdan Catrina (ORCID: https://orcid.org/0000-0002-6914-3902)
- Ponnusamy Saravanan (ORCID: https://orcid.org/0000-0002-9566-2626)
- Akshay Jain (ORCID: https://orcid.org/0000-0001-8515-5359)
- Kabirdev Mandavya
Institutions
- University of British Columbia (CA)
- Novo Nordisk (Denmark) (DK)
- George Eliot Hospital (GB)
- Karolinska Institutet (SE)
- University of Warwick (GB)
- Spaarne Ziekenhuis (NL)
- Kantonsschule Freudenberg (CH)
- Novo Nordisk (India) (IN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1007/s13300-024-01668-6
- Citations
- 15
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.37
Funders
- Novo Nordisk